GT Biopharma, Inc. — Cash Flow Charts
12 years of history · ending 2021-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-187.4% -$10M
$-16M
Free Cash Flow↓-187.2% -$10M
$-16M
Investing Cash Flow↓-575900.0% -$23M
$-23M
Financing Cash Flow↑+606.3% +$36M
$42M
Capex↓-100.0% -$1K
$0
Dividends Paid
—
Stock-Based Comp↓-73.9% -$96M
$34M
D&A↓-100.0% -$1K
$0
SBC Allocated Expense↓-73.9% -$96M
$34M